The HCC-screening guidelines developed by the AASLD and the European Association for the Study of the Liver (EASL) and the Asian Pacific Association for the Study of the Liver (APASL) recommend surveillance for HCC in select high-risk populations with US alone (EASL), in concert with AFP (APASL), or with AFP as an option (AASLD), using a surveillance interval of 6 months. This evidence concerns the gene AFP and hepatocellular carcinoma.